Valuation: Proteomics International Laboratories Ltd

Market Cap 19.84M 13.96M 12.5M 11.5M 10.42M 19.48M 1.33B 137M 55.06M 697M 52.4M 51.28M 2.2B P/E 2025
-5.38x
P/E 2026 -1.8x
Enterprise Value 16.68M 11.73M 10.51M 9.67M 8.76M 16.37M 1.11B 115M 46.27M 586M 44.03M 43.09M 1.85B EV / Sales 2025
12.8x
EV / Sales 2026 4.7x
Free-Float
73.39%
Yield 2025 *
-
Yield 2026 -
23/10 Proteomics International Laboratories Set to Start National Rollout of Two Blood Tests MT
31/08 Proteomics International Laboratories Ltd Reports Earnings Results for the Full Year Ended June 30, 2026 CI
31/08 Proteomics International Laboratories Ltd Auditor Raises 'Going Concern' Doubt CI
02/07 Proteomics International Laboratories Ltd Announces Change of Registered Office Address, effective from July 2, 2026 CI
17/04 Proteomics International Laboratories says restructure, executive appointment and board update RE
17/04 Proteomics International Laboratories Ltd Announces Organizational Restructure CI
17/04 Proteomics International Laboratories Ltd Announces the Retirement of Neville Gardiner from the Board, Effective 17 April 2026 CI
17/04 Proteomics International Laboratories Ltd Appoints Tim Luscombe as Chief Financial Officer, Effective April 17, 2026 CI
25/02 Proteomics International Laboratories Ltd Reports Earnings Results for the Half Year Ended December 31, 2025 CI
23/02 Proteomics International Laboratories Ltd Announces Retirement of Richard Lipscombe as Director, Effective from February 23, 2026 CI
05/02 Proteomics International Laboratories Ltd Announces Stepping Down of David Wood as Joint Company Secretary, Effective February 5, 2026 CI
16/01 Proteomics International Laboratories says Canadian patent secured for Promarkereso diagnostic test for esophageal adenocarcinoma RE
16/01 ASX Midday Sector Update: Electonic Technolgy Rises, Health Services Falls MT
1 day+2.13%
1 month-11.11%
3 months-17.24%
6 months-48.94%
Current year-81.68%
1 week 0.1
Extreme 0.105
0.12
1 month 0.1
Extreme 0.105
0.14
Current year 0.1
Extreme 0.098
0.86
1 year 0.1
Extreme 0.098
0.86
3 years 0.1
Extreme 0.098
1.4
5 years 0.1
Extreme 0.098
1.4
10 years 0.1
Extreme 0.098
1.48
Manager TitleAgeSince
Chief Executive Officer - 19/01/2026
Director of Finance/CFO - 17/04/2026
Director of Finance/CFO - 12/07/2021
Director TitleAgeSince
Director/Board Member - 22/11/2017
Chairman 56 -
Director/Board Member - 08/11/2024
Date Insider Type Main position Quantity % Market Cap. Importance
21/11/24 Free

Founder

800,000 0.6107%
21/11/24 Free

Founder

800,000 0.6107%
21/11/24 Free

Founder

1,000,000 0.7633%
Change 5-day change 1-year change 3-year change Capi.($)
+2.13%-.--%-64.71%-87.50% 13.96M
-0.62%-1.87%+42.87%+64.15% 63.77B
+0.35%+3.20%+14.92%+84.55% 56.37B
+0.53%+1.96%+15.37%+106.81% 54.62B
-2.81%-4.31%+23.50%+47.83% 44.06B
-0.33%-1.93%+19.28%+98.80% 42.11B
+0.55%+2.31%+225.14%+866.21% 41B
+3.27%+47.96%+112.67%+96.48% 34.92B
+1.22%-1.44%+14.89%+47.15% 32.82B
+0.89%+20.55%-40.62%+349.24% 24.7B
Average +0.52%+6.79%+36.33%+167.37% 39.44B
Weighted average by Cap. +0.18%+5.44%+47.95%+177.55%

Financials

2025 2026
Net sales 3.31M 2.33M 2.09M 1.92M 1.74M 3.25M 221M 22.89M 9.19M 116M 8.75M 8.56M 367M 3.37M 2.37M 2.12M 1.95M 1.77M 3.31M 225M 23.29M 9.35M 118M 8.9M 8.71M 373M
Net income -8.11M -5.71M -5.11M -4.7M -4.26M -7.97M -542M -56.09M -22.51M -285M -21.43M -20.97M -899M -8.56M -6.02M -5.39M -4.96M -4.5M -8.4M -572M -59.16M -23.75M -301M -22.6M -22.12M -949M
Net Debt -10.76M -7.57M -6.78M -6.24M -5.65M -10.56M -719M -74.36M -29.85M -378M -28.41M -27.8M -1.19B -3.17M -2.23M -2M -1.84M -1.66M -3.11M -212M -21.9M -8.79M -111M -8.37M -8.19M -351M
Projected Income Statement - Annual - Proteomics International Laboratories Ltd
Logo Proteomics International Laboratories Ltd
Proteomics International Laboratories Ltd is an Australia-based medical technology company. The Company is engaged in predictive diagnostics and bioanalytical services. It specializes in the area of proteomics, the industrial scale study of the structure and function of proteins. It focuses on developing and commercializing diagnostic tests for chronic diseases. Its principal activities fall into three key areas: commercialization of PromarkerD, the predictive test for diabetic kidney disease (DKD) and future kidney function decline in patients with type 2 diabetes; precision diagnostic tests in development: the Promarker pipeline, and specialist accredited analytical services on a commercial basis. Its Promarker pipeline and analytical services include PromarkerEndo, PromarkerEso and OxiDx technology. PromarkerEndo is a prototype diagnostic test for endometriosis identifying up to 90% of patients with the disease. PromarkerEso is a prototype diagnostic test for esophageal cancer.
Employees
-
Date Price Change Volume
30/10/26 $0.1200 +2.13% 48,627
29/10/26 $0.1175 +11.90% 52,405
28/10/26 $0.1050 -12.50% 128,160
27/10/26 $0.1200 -.--% 96,613
26/10/26 $0.1200 -.--% 34,946

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Proteomics International Laboratories Ltd